Skip to main content
Top
Published in: Journal of Nuclear Cardiology 4/2021

01-08-2021 | Cardiac Amyloidosis | Original Article

18F-sodium fluoride PET/MRI myocardial imaging in patients with suspected cardiac amyloidosis

Authors: Mukedaisi Abulizi, MD, Islem Sifaoui, MD, Mijiti Wuliya-Gariepy, MD, Mounira Kharoubi, MD, Jean-Marc Israël, MD, Berivan Emsen, MD, Diane Bodez, MD, Aurélien Monnet, MSc, David Didierlaurent, PhD, Vania Tacher, MD, Alain Luciani, MD, PhD, Thibaud Damy, MD, PhD, Jean-François Deux, MD, PhD, Emmanuel Itti, MD, PhD

Published in: Journal of Nuclear Cardiology | Issue 4/2021

Login to get access

Abstract

Background

We evaluated the diagnostic performance of 18F-NaF PET/MRI in patients with suspected cardiac amyloidosis (CA).

Methods

Twenty-seven consecutive patients underwent myocardial PET 1 hour after injection of 4 MBq/kg 18F-NaF with simultaneous MRI including cine-MRI, T1 and T2 mapping, first-pass and late gadolinium enhancement (LGE). 18F-NaF uptake was measured visually and semi-quantitatively by calculating myocardium-to-blood pool (M/B) ratios. CA was confirmed histologically.

Results

Transthyretin (TTR)-CA was diagnosed in 16 patients, light-chain (AL)-CA in 7, and no-CA in 4. Visual interpretation of 18F-NaF images revealed a relative increase in myocardial uptake in only 3 patients, all with TTR CA, and a relative decrease in 13, including 7 AL CA, 3 no-CA, and 3 TTR CA. M/B ratios were significantly higher in TTR CA (1.00 ± 0.12) than in AL CA (0.81 ± 0.06, P = 0.001) or in no-CA (0.73 ± 0.16, P = 0.006). The optimal M/B cut-off to distinguish TTR CA from AL CA was ≥ 0.90 (Fischer, P = 0.0005). By comparison, classification of patients using 99mTc-HMDP heart-to-mediastinum ratios with the previously published cut-off ≥ 1.21 reached higher significance (P < 0.0001). Among MRI parameters, myocardial T1, LGE score, and extracellular volume were higher in CA than in no-CA patients, 1409 ± 76 vs 1278 ± 35 ms (P = 0.004), 10.35 ± 5.30 vs 3.50 ± 3.42 (P = 0.03), and 46 ± 10 vs 33 ± 8 % (P = 0.01), respectively.

Conclusion

18F-NaF PET/MRI shows good diagnostic performance when semi-quantification is used. However, contrast is low and visual interpretation may be challenging in routine. PET/MRI could constitute a one-stop-shop evaluation of amyloid load and cardiac function in patients needing rapid work-up.
Appendix
Available only for authorised users
Literature
1.
go back to reference Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.CrossRef Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003;349:583-96.CrossRef
2.
go back to reference Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 2013;106:528-40.CrossRef Mohty D, Damy T, Cosnay P, Echahidi N, Casset-Senon D, Virot P, et al. Cardiac amyloidosis: updates in diagnosis and management. Arch Cardiovasc Dis 2013;106:528-40.CrossRef
3.
go back to reference Holzmann M, Nicko A, Kuhl U, Noutsias M, Poller W, Hoffmann W, et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: A retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 2008;118:1722-8.CrossRef Holzmann M, Nicko A, Kuhl U, Noutsias M, Poller W, Hoffmann W, et al. Complication rate of right ventricular endomyocardial biopsy via the femoral approach: A retrospective and prospective study analyzing 3048 diagnostic procedures over an 11-year period. Circulation 2008;118:1722-8.CrossRef
4.
go back to reference Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.CrossRef Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404-12.CrossRef
5.
go back to reference Deux JF, Damy T, Rahmouni A, Mayer J, Plante-Bordeneuve V. Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: A prospective study. Amyloid 2014;21:246-55.CrossRef Deux JF, Damy T, Rahmouni A, Mayer J, Plante-Bordeneuve V. Noninvasive detection of cardiac involvement in patients with hereditary transthyretin associated amyloidosis using cardiac magnetic resonance imaging: A prospective study. Amyloid 2014;21:246-55.CrossRef
6.
go back to reference Galat A, Rosso J, Guellich A, Van Der Gucht A, Rappeneau S, Bodez D, et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 2015;22:210-20.CrossRef Galat A, Rosso J, Guellich A, Van Der Gucht A, Rappeneau S, Bodez D, et al. Usefulness of (99m)Tc-HMDP scintigraphy for the etiologic diagnosis and prognosis of cardiac amyloidosis. Amyloid 2015;22:210-20.CrossRef
7.
go back to reference Van Der Gucht A, Galat A, Rosso J, Guellich A, Garot J, Bodez D, et al. [18F]-NaF PET/CT imaging in cardiac amyloidosis. J Nucl Cardiol 2016;23:846-9.CrossRef Van Der Gucht A, Galat A, Rosso J, Guellich A, Garot J, Bodez D, et al. [18F]-NaF PET/CT imaging in cardiac amyloidosis. J Nucl Cardiol 2016;23:846-9.CrossRef
8.
go back to reference Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S. (18)Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol 2017;25:1559-67.CrossRef Morgenstern R, Yeh R, Castano A, Maurer MS, Bokhari S. (18)Fluorine sodium fluoride positron emission tomography, a potential biomarker of transthyretin cardiac amyloidosis. J Nucl Cardiol 2017;25:1559-67.CrossRef
9.
go back to reference Trivieri MG, Dweck MR, Abgral R, Robson PM, Karakatsanis NA, Lala A, et al. (18)F-sodium fluoride PET/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol 2016;68:2712-4.CrossRef Trivieri MG, Dweck MR, Abgral R, Robson PM, Karakatsanis NA, Lala A, et al. (18)F-sodium fluoride PET/MR for the assessment of cardiac amyloidosis. J Am Coll Cardiol 2016;68:2712-4.CrossRef
10.
go back to reference Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I, et al. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson 2018;20:58.CrossRef Ridouani F, Damy T, Tacher V, Derbel H, Legou F, Sifaoui I, et al. Myocardial native T2 measurement to differentiate light-chain and transthyretin cardiac amyloidosis and assess prognosis. J Cardiovasc Magn Reson 2018;20:58.CrossRef
11.
go back to reference Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 2014;7:133-42.CrossRef Dungu JN, Valencia O, Pinney JH, Gibbs SD, Rowczenio D, Gilbertson JA, et al. CMR-based differentiation of AL and ATTR cardiac amyloidosis. JACC Cardiovasc Imaging 2014;7:133-42.CrossRef
12.
go back to reference Galat A, Van der Gucht A, Guellich A, Bodez D, Cottereau AS, Guendouz S, et al. Early phase 99Tc-HMDP scintigraphy for the diagnosis and typing of cardiac amyloidosis. JACC Cardiovasc Imaging 2017;10:601-3.CrossRef Galat A, Van der Gucht A, Guellich A, Bodez D, Cottereau AS, Guendouz S, et al. Early phase 99Tc-HMDP scintigraphy for the diagnosis and typing of cardiac amyloidosis. JACC Cardiovasc Imaging 2017;10:601-3.CrossRef
13.
go back to reference Wan K, Sun J, Han Y, Liu H, Yang D, Li W, et al. Increased prognostic value of query amyloid late enhancement score in light-chain cardiac amyloidosis. Circ J 2018;82:739-46.CrossRef Wan K, Sun J, Han Y, Liu H, Yang D, Li W, et al. Increased prognostic value of query amyloid late enhancement score in light-chain cardiac amyloidosis. Circ J 2018;82:739-46.CrossRef
14.
go back to reference Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 2017;19:75.CrossRef Messroghli DR, Moon JC, Ferreira VM, Grosse-Wortmann L, He T, Kellman P, et al. Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI). J Cardiovasc Magn Reson 2017;19:75.CrossRef
15.
go back to reference Gagliardi C, Tabacchi E, Bonfiglioli R, Diodato S, Nanni C, Guidalotti P, et al. Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT? J Nucl Cardiol 2016;24:746-9.CrossRef Gagliardi C, Tabacchi E, Bonfiglioli R, Diodato S, Nanni C, Guidalotti P, et al. Does the etiology of cardiac amyloidosis determine the myocardial uptake of [18F]-NaF PET/CT? J Nucl Cardiol 2016;24:746-9.CrossRef
16.
go back to reference Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008;10:54.CrossRef Maceira AM, Prasad SK, Hawkins PN, Roughton M, Pennell DJ. Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis. J Cardiovasc Magn Reson 2008;10:54.CrossRef
17.
go back to reference Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013;6:488-97.CrossRef Karamitsos TD, Piechnik SK, Banypersad SM, Fontana M, Ntusi NB, Ferreira VM, et al. Noncontrast T1 mapping for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 2013;6:488-97.CrossRef
18.
go back to reference Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev 2015;20:133-44.CrossRef Fontana M, Chung R, Hawkins PN, Moon JC. Cardiovascular magnetic resonance for amyloidosis. Heart Fail Rev 2015;20:133-44.CrossRef
19.
go back to reference Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veeranna V, et al. 18F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: Autoradiography study. Circ Cardiovasc Imaging 2015;8:e002954.CrossRef Park MA, Padera RF, Belanger A, Dubey S, Hwang DH, Veeranna V, et al. 18F-florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: Autoradiography study. Circ Cardiovasc Imaging 2015;8:e002954.CrossRef
20.
go back to reference Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-florbetaben PET: A pilot study. J Nucl Med 2016;57:1733-9.CrossRef Law WP, Wang WY, Moore PT, Mollee PN, Ng AC. Cardiac amyloid imaging with 18F-florbetaben PET: A pilot study. J Nucl Med 2016;57:1733-9.CrossRef
21.
go back to reference Wagner T, Page J, Burniston M, Skillen A, Ross JC, Manwani R, et al. Extracardiac (18)F-florbetapir imaging in patients with systemic amyloidosis: More than hearts and minds. Eur J Nucl Med Mol Imaging 2018;45:1129-38.CrossRef Wagner T, Page J, Burniston M, Skillen A, Ross JC, Manwani R, et al. Extracardiac (18)F-florbetapir imaging in patients with systemic amyloidosis: More than hearts and minds. Eur J Nucl Med Mol Imaging 2018;45:1129-38.CrossRef
22.
go back to reference Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: A pilot study using (18)F-flutemetamol positron emission tomography. Ann Nucl Med 2019;33(8):624-8.CrossRef Dietemann S, Nkoulou R. Amyloid PET imaging in cardiac amyloidosis: A pilot study using (18)F-flutemetamol positron emission tomography. Ann Nucl Med 2019;33(8):624-8.CrossRef
23.
go back to reference Van Der Gucht A, Cottereau AS, Abulizi M, Guellich A, Blanc-Durand P, Israel JM, et al. Apical sparing pattern of left ventricular myocardial (99m)Tc-HMDP uptake in patients with transthyretin cardiac amyloidosis. J Nucl Cardiol 2018;25:2072-9.CrossRef Van Der Gucht A, Cottereau AS, Abulizi M, Guellich A, Blanc-Durand P, Israel JM, et al. Apical sparing pattern of left ventricular myocardial (99m)Tc-HMDP uptake in patients with transthyretin cardiac amyloidosis. J Nucl Cardiol 2018;25:2072-9.CrossRef
Metadata
Title
18F-sodium fluoride PET/MRI myocardial imaging in patients with suspected cardiac amyloidosis
Authors
Mukedaisi Abulizi, MD
Islem Sifaoui, MD
Mijiti Wuliya-Gariepy, MD
Mounira Kharoubi, MD
Jean-Marc Israël, MD
Berivan Emsen, MD
Diane Bodez, MD
Aurélien Monnet, MSc
David Didierlaurent, PhD
Vania Tacher, MD
Alain Luciani, MD, PhD
Thibaud Damy, MD, PhD
Jean-François Deux, MD, PhD
Emmanuel Itti, MD, PhD
Publication date
01-08-2021
Publisher
Springer International Publishing
Published in
Journal of Nuclear Cardiology / Issue 4/2021
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-019-01885-8

Other articles of this Issue 4/2021

Journal of Nuclear Cardiology 4/2021 Go to the issue